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HEMOGLOBIN CONCENTRATION IN CHILDREN IN A MALARIA HOLOENDEMIC
AREA IS DETERMINED BY CUMULATED PLASMODIUM FALCIPARUM PARASITE
DENSITIES
HAKAN EKVALL, ZUL PREMJI, STEVE BENNETT, AND ANDERS BJORKMAN
Unit of Infectious Diseases, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden; Department of Parasitology and
Entomology, Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania; Department of Infectious and Tropical
Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
Abstract. In malaria holoendemic areas children are anemic, but the exact influence of falciparum malaria on
hemoglobin (Hb) concentration remains largely unsettled. Prospective data were therefore collected in children  24
months of age during five months in a Tanzanian village. Children with mean asymptomatic parasitemia  400/l
had lower median Hb levels during the study than those with mean density  400/l. The difference was 9.7 g/L
(95% confidence interval [CI] 2.8–17). In children with one or more clinical malaria episodes, the median Hb was
8.3 g/L (95% CI 0.9–16) lower than those without episode. If early treatment failure was recorded, the immediate
effect on Hb was particularly important with a mean drop of 17 g/L. Interestingly, at study-end the Hb concentration
represented a function of the area under the parasitemia curve (AUPC) during the previous five months, adjusting
for age. In conclusion, stepwise deterioration in median Hb levels was found by asymptomatic parasitemia, clinical
malaria episode, and most significantly, treatment failure.
INTRODUCTION
In sub-Saharan Africa, morbidity and mortality from
childhood anemia are severe public health problems.1 The
main contributory causes of anemia are infectious diseases,
nutritional disorders, and hemoglobinopathies.2 Some inves-
tigators cite an iron-deficient diet, hookworm infection, or
schistosomiasis as important causes for anemia,3–5 while oth-
ers have identified malaria as the primary cause. Cross-sec-
tional data have shown deterioration in hemoglobin (Hb)
concentration during malaria transmission and an improve-
ment in Hb with the administration of malaria chemopro-
phylaxis or insecticide-treated bed nets.6–8 These studies do
not fully exclude other conditions associated with malaria,
but Plasmodium falciparum infection appears to be a major
factor in Hb change.9
During infancy, acute malaria episodes have consistently
been associated with low hematocrit  25%,10 mainly oc-
curring from four months of age when children are at risk
of clinical attacks.11,12 However, malaria-associated anemia
may also develop without fever, and be undiagnosed as clin-
ical malaria requiring treatment.13 It has therefore been sug-
gested that children aged  36 months living in an area with
P. falciparum malaria should be routinely treated for malaria
if they have signs of anemia.14
The causal relationship between P. falciparum parasitemia
and Hb concentration in malaria-holoendemic areas is diffi-
cult to establish since most children continually harbor par-
asites.15 Furthermore, the impact on Hb of clinical episodes
and asymptomatic long-term parasitemia may be difficult to
distinguish.16 Cross-sectional data or data from hospitalized
children with severe anemia are unable to capture the dy-
namic relationship between malaria and anemia,17–19 and only
longitudinal data may reveal whether a low Hb level is the
result of recent high parasite density or of longstanding par-
asitemia.20 Furthermore, the pathophysiologic processes of
anemia in malaria include both hemolytic destruction of
erythrocytes and bone marrow suppression,21 implying dif-
ferent time-lags between parasitemia and subsequent effects
on Hb levels,22 and hence the need for prospective data.
The objective of the present study was to prospectively
investigate the impact of symptomatic and asymptomatic
parasitemias on Hb levels in children living in a rural area
with holoendemic malaria.
PATIENTS AND METHODS
Study design. Data for the present study were collected
from a prospective cohort of 211 Tanzanian children partic-
ipating in a randomized controlled intervention trial docu-
menting the effects of regular micronutrient supplementation
on malaria and anemia.23 Descriptive data of the whole co-
hort are presented below, but analyses have been restricted
to the 103 subjects from the placebo group.
The study was conducted from June to November 1995
in Fukayosi village, 30 km west of Bagamoyo town, coastal
Tanzania. Malaria is holoendemic and transmission is peren-
nial with a seasonal peak in July. A census of all children
aged between five and 36 months was performed by mem-
bers of the village committee, and 211 out of 220 children
enumerated were enrolled. No child had to be excluded due
to congenital malformations, clinically decompensated ane-
mia, or migration plans, but four subjects did not participate
in the randomized controlled trial due to having an initial
Hb concentration  50 g/L. Informed consent was obtained
from all parents for 20 weeks’ follow-up and randomization
of the intervention. On enrollment, all children received an
identity number and a ‘‘Mother-and-Child-Health’’ card. De-
mographic data, including age, were obtained from the card
held by each child’s parent, and the approximate distance
from their home to the village dispensary was estimated by
fieldworkers after the start of the study. A medical exami-
nation, including weight, spleen size, and axillary tempera-
ture, was made by one of the investigators and capillary
blood was collected for thick blood films and hematological
measurement. Any history of traditional uvulectomy was
elicited as this could affect Hb concentration.
The children were seen every second week by the research
team at the village dispensary for medical examination and
axillary temperature measurement. These 11 dispensary vis-
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its, including baseline and end surveys, constituted the active
case detection. In addition, six team workers made home
visits three times a week which equaled 56 occasions per
child for supervised administration of placebo or supple-
ment. Any child with a febrile history would then be referred
to the dispensary (‘‘actively passive’’ case detection). Final-
ly, for passive case detection of fever episodes, the village
dispensary was staffed around-the-clock by an assistant doc-
tor and nurse from the team, and daily by at least one of the
principal investigators. Study participation was recorded
both at the bi-weekly dispensary examinations and during
the regular home visits on alternate days. Activities of all
team members were continually supervised by the principal
investigators.
Clinical malaria episodes. A standardized medical ex-
amination was performed in all children with an axillary
temperature  37.5C. This included symptoms and signs of
diseases other than malaria, as well as an estimation of the
clinical severity of the current episode. Capillary blood was
collected for immediate preparation and examination of a
thick blood film, with an additional 40 l pre-diluted for
hematological measurements including Hb concentration.
The pre-diluted specimens were transported by car in a cool-
box for approximately one hr before being analyzed. Results
were available at the dispensary the next day. Fever episodes
judged to be non-malarial in origin were treated accordingly;
co-trimoxazole was not used as an antibiotic due to its an-
timalarial effect. After clinically excluding other febrile con-
ditions, a P. falciparum parasite density  4,000 asexual
parasites per l, estimated during the immediate slide ex-
amination in the field was considered indicative of a clinical
malaria episode requiring treatment.
Malaria episodes were treated with chloroquine syrup
(Elyquine by Elys Ltd, Dar es Salaam, Tanzania) in accor-
dance with Ministry of Health guidelines and administered
by a team nurse. Ten mg/kg of chloroquine base was given
on Day 0, followed by 10 mg/kg on Day 1, and five mg/kg
on Day 2. Every intake was supervised and children were
subsequently observed at the dispensary for 20 min. In case
of vomiting, a full dose was repeated and the child observed
as before. Axillary temperature was measured daily until
Day 3.
Routinely, capillary blood was collected again on Day 3
for thick blood films and hematologic measurement. In case
of persistent fever on Day 2, or clinical deterioration before
Day 3, the child was re-evaluated and blood collected for
hematologic and immediate parasitologic examination; chil-
dren with early treatment failure were given sulfadoxine-
pyrimethamine (SP) and referred to the district hospital, if
necessary. All in-hospital drugs for study children were pro-
vided by the team. Late clinical treatment failures with fever
and parasitemia reappearing between Days 4–13 were treat-
ed with SP and paracetamol. Recurrence of clinical malaria
episodes from Day 14 were assumed to be due to re-infec-
tion and treated as new episodes. All new resumptions of
fever during the 20 weeks’ follow-up were recorded, clas-
sified, and treated as described.
Classification of therapeutic response. Therapeutic re-
sponse within the first 14 days of treatment was defined ac-
cording to World Health Organization (WHO) guidelines.24
However, since subjects’ adherence to the study protocol did
not allow capillary blood collection frequently enough, a
modification was made. Early treatment failure (ETF) was
defined according to the WHO (1996) document, but late
treatment failure (LTF) or adequate clinical response (ACR)
was based on blood and clinical examinations performed two
to four weeks after treatment at the regular dispensary visit
on or next after Day 14.
Early treatment failure was defined by the following cri-
teria:
● Danger signs (unconsciousness, prostration, convulsion,
excessive vomiting, or no oral intake) within 72 hr, and
asexual P. falciparum parasitemia.
● Temperature  37.5C after 48 hr, with asexual parasit-
emia  Day 0.
● Temperature  37.5C after 72 hr with asexual parasit-
emia.
● Asexual parasitemia after 72 hr  25% of Day 0.
Late treatment failure was defined as:
● Danger signs and asexual parasitemia during Days 4–14,
without meeting the criteria for ETF.
● Temperature  37.5C and asexual parasitemia during
Days 4–14, without meeting the criteria for ETF.
Adequate clinical response was defined as:
● Temperature  37.5C with asexual parasitemia during
Days 15–28, without meeting the criteria for ETF or LTF.
● No asexual parasitemia during Days 15–28, without meet-
ing the criteria for ETF or LTF.
Scheduled blood collections. Blood samples were drawn
from all children at the baseline and end surveys and in two
surveys after approximately two and four months. Capillary
blood was also collected twice during each clinical malaria
episode and once at follow-up. All collections included a
blood slide and Hb estimation.
Laboratory tests and quality control. Thick blood films
were stained with 5% Giemsa stain, and the asexual parasite
density was estimated by counting parasites against 200
white blood cells (WBC), assuming a standard WBC count
of 8,000/l.25 If less than 10 parasites were recorded per 200
leucocytes, estimation was made against another 300 WBCs.
All P. falciparum parasitemias, whether single or dual in-
fections, were used in the analyses. The slides of febrile
patients were first examined in the field. All slides were later
read by the investigator who examined all blood slides, with
10% re-checked by two blinded, independent microscopists.
The between-reader variability of parasite density was  1.5
log.
For hematologic measurements, an automated hematolog-
ic analyser (Cell-Dyn 610, Abbot Laboratories) was used.
Daily commercial quality controls assessed the coefficient of
variation for the within-sample precision of the Hb estimate
at  1%, both for immediate run samples and after a six-
hour delay in analysis. Capillary blood collection was stan-
dardized to prevent pre-analytic bias in Hb estimation. All
fingerprick specimens were collected during morning hours,
if possible. The children were sitting upright in their moth-
ers’ laps, allowing free flow of capillary blood. Two team
members performed all blood collections.
Screening was performed for conditions potentially af-
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TABLE 1
Descriptive data from baseline and end surveys by age
Age group* Survey
Mean Hb
g/L (SD)
Hb  70 g/L
No. (%)
Parasitemic children
No. (%)
Parasite density/l
geometric mean
of all slides
 24 months
 24 months
 24 months
 24 months
All
All
Baseline
End
Baseline
End
Baseline
End
80 (14)
88 (14)
97 (14)
96 (13)
89 (16)
92 (14)
16/46 (35%)
6/43 (14%)
1/57 (2%)
2/54 (4%)
17/103 (16%)
8/97 (8%)
43/46 (94%)
35/43 (81%)
50/57 (88%)
49/54 (91%)
93/103 (90%)
84/97 (86%)
3,100
670
920
1,000
1,620
840
* Age at study-end. Hb  hemoglobin; SD  standard deviation.
fecting anemia, but no children had to be excluded from the
analyses. Sickle cell hemoglobin was assessed by a solubility
test and confirmed by Hb electrophoresis. Human immuno-
deficiency virus (HIV) was investigated by enzyme-linked
immunosorbent assay (ELISA) (Behring) and confirmed by
Western blot. The HIV results were only available after
study termination and were blinded; hence, no pre-test coun-
seling was performed. Helminthic infections were investi-
gated but not quantified in a single stool specimen by the
formalin-ether concentration technique.26
Statistical methods. The data were analyzed using Epi-
Info 6.2 and JMP 3.1 (SAS Institute Inc.). Clinical malaria
incidence rates were calculated based on person-time atten-
dance during home visits. Proportions were compared with
the aid of Pearson’s chi-square or Fisher’s exact test. Paired
or two-sample t-tests and analysis of variance were used for
normally distributed continuous data; parasite densities were
normalized after adding one to each count, using logarithmic
transformation. The Wilcoxon rank-sum test was used for
non-normal continuous data. A statistical significance level
of 0.05, two-tailed test, was generally employed.
Ethical considerations. All work was performed in ac-
cordance with the guidelines for human experimentation in
clinical research stated in the research approval from the
ethical committees of the Karolinska Institute in Stockholm
and the Muhimbili College of Health Sciences in Dar es
Salaam, Tanzania. Parents of study subjects provided oral
informed consent.
RESULTS
Full cohort descriptives. Study subjects. The 211 chil-
dren of the full study cohort had a mean age of 19 months
(SD 8.5) at enrollment; 51% were male. The frequency of
home-visit attendance revealed that 88% of the children’s
total person-time was observed and recorded in the study.
Study participation was evenly distributed over the 20 study
weeks and unaffected by distance from home to dispensary
(data not shown). The median attendance at the regular bi-
weekly dispensary examinations was 100%, with 190 chil-
dren (90%) present at  8 of the 11 scheduled visits. The
45 children living furthest away from the dispensary had a
slightly lower attendance record with a median of 91% (in-
terquartile range [IQR] 73–100).
Biochemical and clinical observations. Blood was col-
lected on 1,540 occasions in the 211 study subjects, corre-
sponding to a median of seven observations per child (range
1–19). A median of four (IQR 3–4) blood collections were
made in children with no clinical malaria episodes recorded
during the study. There was no fever or ongoing drug treat-
ment at the time of 856 (56%) blood collections. Out of all
blood slides, 1,092 (73%) were single infections with P. fal-
ciparum, 183 (12%) were dual infections that included P.
falciparum, and 14 (1%) were single infections with another
species. No child remained aparasitemic over the full study
period.
Out of 388 fever episodes recorded during the five study
months, 284 were diagnosed and treated as malaria episodes.
Forty percent of fevers were detected at the scheduled bi-
weekly visits and 60% upon reporting to the dispensary. A
total of 103 (36%) malaria cases were diagnosed in the first
month; study onset coincided with peak malaria transmission
at the end of the rainy season. The incidence of clinical
malaria episodes subsequently dropped and remained con-
stant over the subsequent four months.
During the study period, three children were referred to
hospital due to gastroenteritis and malaria, and one of them
received a blood transfusion. The children were continually
followed during and after hospital admission. The preva-
lence of the sickle-cell trait was 23%. No child was found
positive for HIV infection. Hookworm infection was detect-
ed in 13% of the children, but there was no statistical as-
sociation with Hb concentration, adjusting for age (data not
shown).
Placebo group analyses. The following analyses on the
relationship between parasitemia and Hb levels are based on
data from the 103 children of the placebo group who did not
receive micronutrient supplementation.
Age dependence. Data from the cross-sectional surveys at
the beginning and end of the study are displayed in Table 1.
Children aged  24 months at study-end had initially sig-
nificantly lower Hb and more often severe anemia, i.e., Hb
 70 g/L, than older children (P  0.001), but this difference
was less apparent at the end of study and not statistically
significant for the prevalence of severe anemia (P  0.11).
There was also a statistically significant reduction in parasite
prevalence and mean density in children  24 months over
the five-month study period (Table 1). The longitudinal data
presented in Table 2 revealed a marked age dependence of
malaria indices, such as the clinical malaria incidence rate
and parasite density at treatment onset. Early chloroquine
treatment failure rate was also highest in the youngest chil-
dren.
Clinical malaria episodes. The parasite density on Day 0
of first or only clinical malaria episode was linearly related
to the subsequent drop in Hb after 72 hr (P  0.001; data
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TABLE 2
Clinical falciparum malaria episodes, treatment responses to chloroquine, and asymptomatic parasitemias by age
Age at study-end
18 months 18–23 months  24 months All
No. of children at baseline 20 26 57 103
Children with at least one clinical malaria
episode recorded, no. (%) 14 (70%) 21 (81%) 28 (49%) 63 (61%)
Mean incidence rate of clinical malaria epi-
sodes/person-month (95% CI) 0.38 (0.24–0.52) 0.29 (0.19–0.39) 0.16 (0.11–0.22) 0.24 (0.19–0.29)
Parasite density/l at start of antimalarial
treatment, geometric mean (IQR) of all
episodes 25,000 (7,800–70,000) 11,000 (5,000–39,000) 9,000 (4,500–25,000) 13,000 (5,000–41,000)
Children with early treatment failure, no.
(%) 8 (40%) 3 (12%) 3 (5%) 14 (14%)
Children with late treatment failure, no. (%) 4 (20%) 5 (19%) 8 (14%) 17 (17%)
Asymptomatic parasite density/l, geometric
mean (IQR) 610 (400–5,000) 1,000 (530–6,300) 740 (600–5,000) 790 (500–5,000)
IQR  interquartile range.
TABLE 3
Change in hemoglobin (Hb) (g/L) between Day 0 and Day 3 in each subject’s first or only clinical falciparum malaria episode
Chloroquine treatment responses
Change in Hb 72 hours
after starting chloroquine treatment, g/L (SE)
Parasitemia  20,000/l on Day 0 Parasitemia  20,000/l on Day 0 All
Early treatment failures
Late treatment failure  adequate clinical
responses
1 (3), n  4
2 (1), n  25
17 (3), n  6
3 (2), n  13
10 (4), n  10
2 (1), n  38
n  number of patients.
not shown). Early failure of chloroquine treatment was as-
sociated with an immediate reduction of Hb concentration
within 72 hr, but this was only evident in the presence of
hyperparasitemia (Table 3). The magnitude of the fall was
unrelated to age, after adjusting for parasite density. Treat-
ment failure was not associated with hyperparasitemia per
se (data not shown). In 33 of 46 children  24 months the
criteria for chloroquine treatment failure was not fulfilled at
any time during the study. In these children, an increasing
incidence of clinical malaria episodes was associated with a
linear decline in individual median Hb, from 88 to 64 g/L
(P  0.03; Figure 1). The interactive effects of clinical ma-
laria episodes, mean asymptomatic parasitemias, and number
of negative blood-slides on individual median Hb levels are
presented in Figure 2. In children  24 months, hemoglobin
levels were only marginally affected by clinical episodes and
parasite densities (Figure 2B). In contrast, in children  24
months the effect was significant (Figure 2A), and those with
at least one clinical malaria episode had 8.3 g/L (95% CI,
0.9–16.0) lower median Hb than those without any episode.
Asymptomatic parasitemia. As seen in Table 2, the overall
geometric mean parasite density during asymptomatic inter-
vals and occurrence of negative blood-slides were not as-
sociated with age. This relationship was confounded, how-
ever, by SP treatment. Sulfadoxine-pyrimethamine treatment,
mainly given to the youngest children, resulted in lower par-
asite density and prevalence in subsequent asymptomatic fol-
low-up specimens; the geometric mean parasitemia in chil-
dren treated with SP at any time during the study was 200
parasites/l compared to 1,150 in children without such
treatment (P  0.003). As shown in Figure 2A, children 
24 months with asymptomatic mean parasite density  400/
l had 9.7 g/L (95% CI 2.8–17.0) lower median Hb levels
than those with mean density  400/l. Similarly, children
who were constantly parasitemic had 10.0 g/L (95% CI 3.3–
17.0) lower median Hb than those with  2 negative blood-
slides during the five-month study period.
Malaria indices and Hb. When combined, the malaria in-
dices markedly affected individual median Hb in children 
24 months (Table 4). For example, children with no clinical
malaria episode and a geometric mean asymptomatic para-
site density  400/l had a median Hb of 104 g/L. This
level decreased to 85 g/L if at least one clinical malaria
episode occurred and to 83 g/L if the mean asymptomatic
parasitemia increased to  400/l. In case of both, the me-
dian Hb fell to 79 g/L. To reach a median Hb concentration
 100 g/L, children  24 months in this study had to have
no clinical malaria episode, a mean parasitemia  25 para-
sites/l, and at least two negative blood-slides. No cohort
child  24 months had Hb  110 g/L consistently, the Cen-
ters for Disease Control and Prevention (CDC) criterion for
a normal Hb level.27
Cumulated parasitemia. The association between simul-
taneous parasite density and Hb was inconsistent; there was
an association in the baseline survey, but not in the end
survey, nor in each subject’s first or only clinical malaria
episode (data not shown). Similarly, the geometric mean
symptomatic parasitemia and the occurrence of symptomatic
parasitemias  20,000/l did not influence the individual
median Hb during the study period, even after adjusting for
age and SP treatment. Furthermore, there was no association
between baseline Hb and parasitemia in the first malaria ep-
isode, but baseline parasitemia was significantly related to
Hb in the first malaria episode. To allow for a longer influ-
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FIGURE 1. Association between incidence of clinical malaria ep-
isodes and individual median Hb in children aged  24 months not
fulfilling the criteria for chloroquine treatment failure and not re-
ceiving treatment with sulfadoxine-pyrimethamine (SP). Correlation
coefficient, r  0.38; P  0.03.
ence of parasitemia, each individual’s parasite load over five
months was estimated as the area under the parasitemia
curve (AUPC) by multiplying the geometric mean of two
consecutive parasite densities with number of days between
measurements (Figure 3). Adjusting for age, the AUPC was
highly significant in explaining the final Hb concentration.
Using only asymptomatic, symptomatic, or cross-sectional
parasitemia recordings produced a less satisfactory fit of the
regression model.
Severe anemia. Severe anemia, defined as median Hb 
70 g/L, was recorded in 7 of 46 children aged  24 months
despite optimal case management using local treatment
guidelines. Children with severe anemia were unlikely to
have had any negative blood-slides during the study, relative
risk (RR) 0.3 (95% CI 0.09–1.0). They had higher mean
asymptomatic parasite density (2,600/l) than children with-
out severe anemia (730/l; P  0.01), and their mean clin-
ical malaria incidence rate was 0.56/person-month compared
to 0.29 (P  0.01).
Within-individual Hb fluctuations. The mean Hb improve-
ment from study start to end in children without clinical
malaria episodes was 2.1 g/L in subjects  24 months and
1.2 g/L in those  24 months. The mean variation in indi-
vidual Hb estimates during the study was 14 g/L and 12 g/
L, respectively. Hence, in addition to a net increase in Hb,
there was substantial individual fluctuation in the repeated
Hb estimates. Variation in Hb due to changes in parasitemia
would presumably occur. The geometric mean within-indi-
vidual variation in parasitemia in the same asymptomatic
individuals was 4,200 (IQR 2,200–9,300) parasites/l; this
variation was, however, unrelated to fluctuations in Hb (P 
0.60). In contrast, the fluctuations in Hb were significantly
related to episodes of both vomiting and diarrhea (data not
shown).
DISCUSSION
To determine the influence of malaria parasitemia on Hb
concentration, children in the present study were followed
prospectively for five months in a clinical setting at village
level under optimal local diagnostic and treatment condi-
tions. Although mostly mild and moderate malaria cases
abound at community level, such cases may precede severe
disease manifestations, including severe anemia, that are
seen in children admitted to hospital. Furthermore, it is prob-
ably more appropriate to study the basic interaction between
parasite and host at community level since this interaction
is less distorted by complicating factors, including antima-
larial treatment before the onset of severe symptoms requir-
ing hospitalization. In addition, a longitudinal perspective
was considered essential when trying to capture a pathoge-
netic time-lag of the effects of parasitemia on Hb.
Capillary Hb estimates in children are prone to pre-ana-
lytic variation and bias.28 In the present study, dehydration
due to vomiting and diarrhea was associated with within-
individual fluctuations in Hb concentration. In addition, tech-
nical sampling bias may be a problem in children who are
sick and less cooperative during capillary blood collection.
To reduce the effects of methodological variability in re-
peated capillary Hb estimates, the median of an individual’s
Hb readings over five months was used. This value, reflect-
ing the individual’s long-term Hb-profile, was correlated
with clinical and parasitological data collected during the
study period. The overall five-month observation time ex-
tended well beyond the expected regeneration time of red
blood cells, allowing for an Hb ’steady state’ level to be
reached under the present diagnostic and treatment condi-
tions.
The differences in parasitemia and Hb between the base-
line and end surveys probably reflect the intensified malaria
case management during the study. The laboratory indices
of children  24 months were unchanged from study start
to end, whereas those of children  24 months showed only
modest improvement (Table 1). The continued high preva-
lence of parasitemia and low mean Hb levels at the end
survey represent the end results of five months of prompt
malaria case management in a holoendemic area. Whether
the use of sulfadoxine-pyrimethamine instead of chloroquine
as first-line treatment would have improved these results re-
mains undetermined. However, the median Hb during the
study remained unaffected by SP treatment, emphasizing its
temporary impact on Hb levels. This, therefore, demon-
strates the limitations of ‘case management’ as the only ma-
laria control tool, using current treatment guidelines.
There was an excessive vulnerability to symptomatic ma-
laria in the youngest children (Table 2). In addition, 40% of
children  18 months were affected by early chloroquine
treatment failure during the five months’ observation period,
leading to a concomitant drop in Hb, especially following
hyperparasitemia (Table 3).29 Hence, it was predominantly
the youngest children who suffered attacks of severe acute
hemolytic anemia. All treatment failures received prompt
second-line therapy with SP, which at follow-up compensat-
ed for the immediate loss in Hb, most likely by subsequent
reduction in the asymptomatic parasitemia level and possibly
clinical malaria incidence rate. Since the availability of ef-
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FIGURE 2. Effects of malaria parasitemia and clinical malaria episodes on mean of individual median Hb, g/L (SE). Figure A represents
children aged  24 months at study-end and Figure B, children  24 months.
Column 1  overall mean Hb
Column 2  no negative blood-slide
Column 3   1 negative blood-slide
Column 4   2 negative blood-slides
Column 5  geometric mean asymptomatic parasitemia  400 parasites/l
Column 6  geometric mean asymptomatic parasitemia  400 parasites/l
Column 7   1 clinical malaria episode
Column 8  no clinical malaria episodes
fective second-line antimalarial therapy at village level may
be inconsistent under non-study conditions, it is likely that
acute anemia due to early chloroquine treatment failure is a
major preventable contributor of anemia currently observed
in young children. Furthermore, chloroquine treatment, even
without therapeutic failure, could not prevent a general re-
duction in Hb levels (Figure 1). It was not possible to de-
termine whether this was due to cumulated recurrent loss of
Hb during the repeated malaria episodes per se, or to a high-
er post-treatment asymptomatic parasitemia level compared
to SP.
There was a clear dose-response relationship between P.
falciparum parasitemia and Hb in children younger than two
years (Figure 2A). In addition, the Hb concentration at
study-end was found to be a cumulative function of the pre-
vious parasitemias over five months, adjusting for age. In
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TABLE 4
Combined effects of malaria indices on mean of individual median hemoglobin (Hb) g/L (SE) in children  24 months old
No. clinical malaria episodes
None 1
No. negative blood-slides
1 None
No. clinical malaria episodes
None
 1
104 (7.0), n  10
82 (2.0), n  38
83 (2.2), n  30
78 (2.6), n  25
Asymptomatic parasite density
 400 mm3
 400 mm3
104 (7.0), n  8
83 (2.2), n  31
85 (3.2), n  18
79 (1.8), n  44
90 (3.9), n  26
80 (2.6), n  22 80 (1.9), n  53
SE  standard error.
n  number of patients.
FIGURE 3. Hemoglobin (Hb) (g/L) at study-end as a function of
the area under parasitemia curve (AUPC) during five months. Ad-
justing for age, the attached table describes the regression procedure
of Hb at end on AUPC and age. AUPC   [(Dt1  Dt)(Pt1  Pt)/
2], where D  day and P  log parasite density.
the formula for AUPC each symptomatic parasitemia was
given a weight of three days, out of a total study duration
of 140 days. The extension of duration of symptomatic par-
asitemias was prevented by immediate drug intervention in
the case of treatment failure. In addition, logarithmic trans-
formation of parasite counts further reduced the relative im-
portance of high symptomatic parasite densities. Hence, in
the sampling scheme used, symptomatic parasitemias were
restricted both in time and magnitude compared to asymp-
tomatic parasitemias. Considering the excellent model fit un-
der this scheme, it seems plausible that asymptomatic para-
sitemias were relatively more important than symptomatic
parasite densities in determining the final Hb concentration.
Asymptomatic parasitemia may be beneficial in inducing
and sustaining partial immunity against malaria.30 However,
a significant drawback is the suppression of Hb concentra-
tion. The absolute and prolonged impact of asymptomatic
parasitemia on Hb levels could not be determined since no
child was aparasitemic over the full study period. Moreover,
all cohort children  24 months were anemic. Hence, it was
not possible to determine an asymptomatic parasitemia cut-
off level which would hypothetically allow for semi-immu-
nity to develop without leading to anemia.22
Hemoglobin levels only recovered when at least two of
the measured malaria indices were ameliorated, i.e., when
most of the malaria was eliminated (Table 4). This empha-
sizes the need for drugs to eliminate parasitemia for a certain
period of time in order to improve anemia.31 From this per-
spective, antimalarial treatment with drugs of short duration,
e.g., chlorproguanil-dapsone or artemisinine derivatives,
may be less effective against anemia under perennial trans-
mission conditions because of more frequent symptomatic
or asymptomatic re-infections than after treatment with
drugs that are slowly eliminated. Even if such re-infections
are adequately treated when symptomatic, there may be dif-
ficulties in restoring long-term Hb concentration, particularly
in children  24 months. Similarly, recurrent antimalarial
drug treatment in small children with parasitemia, but no
fever, may be successful in preventing anemia if performed
with an antimalarial with relatively long action time, e.g.,
SP.14,32 However, the effects of such repeated abortion of
chronic asymptomatic parasitemia on the development of
partial antimalarial immunity need to be considered.33,34
At study-end, the prevalence of parasitemia in children 
24 months old was lower than in those  24 months (Table
1). This possibly reflected the frequent use of SP treatment
in small children, although Hb was lower in children  24
months at study-end. This may be related to the fact that
young children are more prone to develop anemia as a com-
plication to malaria than their older peers. However, in the
regression model of Figure 3, the two-way interaction term
between age and parasitemia was not significant (data not
shown), suggesting that at similar levels of parasitemia, the
effect on Hb did not differ between ages. However, young
age per se was also related to lower Hb, and since parasite
densities are highest in youngest children, anemia in this age
group may be an independent but additive result of low age
and high parasite densities. In addition to malaria, other age-
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related factors, e.g., iron deficiency or other infections, may
also contribute to anemia. Hookworm infection, however,
was rare and not related to Hb levels in this study, consistent
with the age-dependent acquirement of infection.35 Light
hookworm infections have been implicated as a cause of
anemia in populations with poor iron status, but in children
 3 years, hookworm egg counts rarely reach the concen-
tration known to affect Hb concentration.3,5 Although addi-
tional stool samples may have detected a few more infected
children, in this cohort of anemic children hookworm infec-
tion was most likely of inferior importance.
In conclusion, our data from an area of high malaria trans-
mission show that anemia in early childhood is highly as-
sociated to falciparum malaria but that the Hb value is in-
fluenced by several partly independent factors, i.e., a cu-
mulative effect by continuous asymptomatic parasitemia,
and an acute effect by a clinical episode, especially in con-
nection with treatment failure. Prompt malaria case manage-
ment, including sulfadoxine-pyrimethamine as a second-line
drug, appears to restore short-term Hb values but does not,
on its own, sufficiently improve the long-term Hb levels in
children below 24 months of age.
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